SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lisinopril / Hydrochlorothiazide Formulation

Version 1.8  Revision Date: 09.04.2021  SDS Number: 4575502-00009  Date of last issue: 10.10.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Lisinopril / Hydrochlorothiazide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
              Piercetown
              A86 HD21 Dunboyne, Ireland
   Telephone : 908-740-4000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1A : H360D: May damage the unborn child.
   Specific target organ toxicity - repeated exposure, Category 1 : H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Danger
   Hazard statements : H360D  May damage the unborn child.
                     H372  Causes damage to organs through prolonged or repeated exposure.
   Precautionary statements : Prevention:
                            P201  Obtain special instructions before use.
                            P264  Wash skin thoroughly after handling.
                            P270  Do not eat, drink or smoke when using this product.
Lisinopril / Hydrochlorothiazide Formulation

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:
Hydrochlorothiazide
Lisinopril

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form combustible dust concentrations in air during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures
Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5 200-403-3</td>
<td>STOT RE 1; H372 (Kidney, Parathyroid gland)</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>Repr. 1A; H360D STOT RE 2; H373 (Kidney)</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice: In the case of accident or if you feel unwell, seek medical ad-
vice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Chlorine compounds
Sulphur oxides
Metal oxides
Oxides of phosphorus

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

7.3 Specific end use(s)

Specific use(s): No data available
SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>OELV - 8 hrs (TWA) (Respirable dust)</td>
<td>4 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA) (inhalable dust)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Starch, oxidized</td>
<td>65996-62-5</td>
<td>OELV - 8 hrs (TWA) (Dust)</td>
<td>1 mg/m³</td>
<td>IE OEL</td>
</tr>
</tbody>
</table>

Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used.

8.2 Exposure controls

Engineering measures
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection Material: Chemical-resistant gloves

Skin and body protection: Work uniform or laboratory coat.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)
SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- **Physical state**: solid
- **Colour**: No data available
- **Odour**: odourless
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: May form combustible dust concentrations in air during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Flash point**: Not applicable
- **Auto-ignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Decomposition temperature**: No data available
- **pH**: No data available
- **Viscosity**: Not applicable
- **Viscosity, kinematic**: Not applicable
- **Solubility(ies)**: No data available
- **Water solubility**: No data available
- **Partition coefficient: n-octanol/water**: Not applicable
- **Vapour pressure**: Not applicable
- **Relative density**: No data available
- **Density**: No data available
- **Relative vapour density**: Not applicable
- **Particle characteristics**: No data available

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: Not applicable
Molecular weight: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form combustible dust concentrations in air during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Hydrochlorothiazide:
Acute oral toxicity: LD50 (Rat): > 2,750 mg/kg
LD50 (Mouse): > 2,830 mg/kg
Acute toxicity (other routes of administration): LD50 (Rat): 990 mg/kg
Application Route: Intravenous
Lisinopril / Hydrochlorothiazide Formulation

LD50 (Mouse): 590 mg/kg
Application Route: Intravenous

Lisinopril:
Acute oral toxicity: LD50 (Rat): > 20,000 mg/kg
LD50 (Mouse): > 20,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Hydrochlorothiazide:
Species: Rabbit
Result: No skin irritation

Lisinopril:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Hydrochlorothiazide:
Species: Rabbit
Result: Mild eye irritation

Lisinopril:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Lisinopril:
Test Type: Maximisation Test
Exposure routes: Dermal
Result: negative
Germ cell mutagenicity
Not classified based on available information.

Components:

Hydrochlorothiazide:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Chinese hamster ovary cells
  Result: negative
- Test Type: sister chromatid exchange assay
  Test system: Chinese hamster ovary cells
  Result: positive
- Test Type: in vitro assay
  Test system: mouse lymphoma cells
  Result: positive

Genotoxicity in vivo:
- Test Type: Chromosomal aberration
  Species: Chinese hamster
  Cell type: Bone marrow
  Result: negative
- Test Type: in vivo assay
  Species: Mouse
  Cell type: Bone marrow
  Result: negative

Germ cell mutagenicity: Assessment
Weight of evidence does not support classification as a germ cell mutagen.

Lisinopril:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: Alkaline elution assay
  Test system: rat hepatocytes
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.
**Components:**

### Hydrochlorothiazide:

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse, male</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>equivocal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male and female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Lisinopril:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>105 weeks</td>
</tr>
<tr>
<td>NOAEL</td>
<td>90 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>92 weeks</td>
</tr>
<tr>
<td>NOAEL</td>
<td>135 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Reproductive toxicity**

May damage the unborn child.

### Components:

### Hydrochlorothiazide:

Effects on fertility: Test Type: Fertility  
Species: Rat, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 4 mg/kg body weight  
Result: Effects on fertility

Effects on foetal development: Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Lisinopril / Hydrochlorothiazide Formulation

Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No teratogenic effects

Lisinopril:
Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: positive, No teratogenic effects

Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Symptoms: Total Resorptions / resorption rate
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Causes damage to organs through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:
Target Organs: Kidney, Parathyroid gland
Assessment: Causes damage to organs through prolonged or repeated exposure.
### Lisinopril / Hydrochlorothiazide Formulation

**Lisinopril:**
- **Exposure routes:** Ingestion
- **Target Organs:** Kidney
- **Assessment:** May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Hydrochlorothiazide:**
- **Species:** Rat, male and female
- **LOAEL:** 10 mg/kg
- **Application Route:** Oral
- **Exposure time:** 2 yr
- **Target Organs:** Kidney, Parathyroid gland

**Species:** Mouse, male and female
- **NOAEL:** 300 - 550 mg/kg
- **Application Route:** Oral
- **Exposure time:** 2 yr
- **Remarks:** No significant adverse effects were reported

**Species:** Dog
- **Application Route:** Oral
- **Exposure time:** 9 Months
- **Target Organs:** Parathyroid gland

**Lisinopril:**
- **Species:** Rat
- **LOAEL:** < 3,650 mg/kg
- **Application Route:** Oral
- **Exposure time:** 1 yr
- **Target Organs:** Kidney

**Species:** Dog
- **LOAEL:** < 840 mg/kg
- **Application Route:** Oral
- **Exposure time:** 4 Weeks
- **Target Organs:** Kidney

**Aspiration toxicity**

Not classified based on available information.

**Components:**

**Hydrochlorothiazide:**

No aspiration toxicity classification
11.2 Information on other hazards

**Endocrine disrupting properties**

**Product:**

**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Experience with human exposure**

**Components:**

**Hydrochlorothiazide:**

- **Eye contact:** Symptoms: Eye irritation
- **Ingestion:** Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

**Lisinopril:**

- **Ingestion:** Symptoms: Dizziness, Headache, Fatigue, Diarrhoea, Nausea, Cough, Lowered blood pressure, electrolyte imbalance
  Remarks: May damage the unborn child.

**SECTION 12: Ecological information**

12.1 Toxicity

**Components:**

**Hydrochlorothiazide:**

- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l
  Exposure time: 96 h
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): > 500 mg/l
  Exposure time: 48 h

**Lisinopril:**

- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): 20,000 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202

12.2 Persistence and degradability

**Components:**

**Hydrochlorothiazide:**

- **Stability in water:** Hydrolysis: 46.2 % (96 h)
SAFETY DATA SHEET
going according to Regulation (EC) No. 1907/2006

Lisinopril / Hydrochlorothiazide Formulation

Version 1.8 Revision Date: 09.04.2021 SDS Number: 4575502-00009 Date of last issue: 10.10.2020 Date of first issue: 08.07.2019

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good
14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
**SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

**Lisinopril / Hydrochlorothiazide Formulation**

---

**Version** 1.8  
**Revision Date:** 09.04.2021  
**SDS Number:** 4575502-00009  
**Date of last issue:** 10.10.2020  
**Date of first issue:** 08.07.2019

<table>
<thead>
<tr>
<th><strong>Full text of H-Statements</strong></th>
</tr>
</thead>
</table>
| H360D : May damage the unborn child.  
| H372 : Causes damage to organs through prolonged or repeated exposure.  
| H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.  

<table>
<thead>
<tr>
<th><strong>Full text of other abbreviations</strong></th>
</tr>
</thead>
</table>
| Repr. : Reproductive toxicity  
| STOT RE : Specific target organ toxicity - repeated exposure  
| IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1  
| IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)  

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet:  

**Classification of the mixture:**

<table>
<thead>
<tr>
<th>Classification procedure:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calculation method</td>
</tr>
</tbody>
</table>

17 / 18
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Lisinopril / Hydrochlorothiazide Formulation

Version 1.8
Revision Date: 09.04.2021
SDS Number: 4575502-00009
Date of last issue: 10.10.2020
Date of first issue: 08.07.2019

STOT RE 1 H372 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN